Get the Stockscreener App
1.38
2.13%
-0.03
After Hours:
1.40
0.02
+1.45%
Biomea Fusion Inc stock is traded at $1.38, with a volume of 844.89K.
It is down -2.13% in the last 24 hours and up +8.66% over the past month.
Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.
See More
Previous Close:
$1.41
Open:
$1.44
24h Volume:
844.89K
Relative Volume:
0.59
Market Cap:
$99.77M
Revenue:
-
Net Income/Loss:
$-44.95M
P/E Ratio:
-1.5462
EPS:
-0.8925
Net Cash Flow:
$-56.37M
1W Performance:
-0.72%
1M Performance:
+8.66%
6M Performance:
+9.52%
1Y Performance:
-16.87%
1-Day Range:
$1.36
$1.46
1-Week Range:
$1.32
$1.51
52-Week Range:
$0.8719
$2.99
Biomea Fusion Inc Stock (BMEA) Company Profile
Name
Biomea Fusion Inc
Sector
Industry
Phone
(650) 980-9099
Address
1599 INDUSTRIAL ROAD, SAN CARLOS
Compare BMEA vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BMEA
Biomea Fusion Inc
|
1.38 | 106.28M | 0 | -44.95M | -56.37M | -0.8925 |
VRTX
Vertex Pharmaceuticals Inc
|
529.59 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
649.81 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
916.80 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
313.04 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.99 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Biomea Fusion Inc Stock (BMEA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-13-26 | Initiated | Rodman & Renshaw | Buy |
| Aug-28-25 | Initiated | Jefferies | Buy |
| Jun-03-25 | Resumed | Piper Sandler | Overweight |
| Oct-09-24 | Initiated | Edward Jones | Buy |
| Sep-27-24 | Upgrade | Rodman & Renshaw | Neutral → Buy |
| Sep-27-24 | Upgrade | Truist | Hold → Buy |
| Aug-29-24 | Initiated | CapitalOne | Overweight |
| Jun-11-24 | Downgrade | Truist | Buy → Hold |
| Jun-07-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Apr-02-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-06-24 | Initiated | Truist | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Outperform |
| Jun-26-23 | Downgrade | Jefferies | Buy → Hold |
| May-12-23 | Initiated | Barclays | Overweight |
| Mar-29-23 | Reiterated | Oppenheimer | Outperform |
| Mar-28-23 | Reiterated | H.C. Wainwright | Buy |
| Feb-24-23 | Initiated | Citigroup | Buy |
| Jun-02-22 | Resumed | H.C. Wainwright | Buy |
| Jan-12-22 | Initiated | H.C. Wainwright | Buy |
| Dec-17-21 | Initiated | Oppenheimer | Outperform |
| May-11-21 | Initiated | JP Morgan | Overweight |
| May-11-21 | Initiated | Jefferies | Buy |
| May-11-21 | Initiated | Piper Sandler | Overweight |
View All
Biomea Fusion Inc Stock (BMEA) Latest News
Price to earnings forward of Biomea Fusion, Inc. – NASDAQ:BMEA - TradingView
Price to sales forward of Biomea Fusion, Inc. – NASDAQ:BMEA - TradingView
Price to book forward of Biomea Fusion, Inc. – NASDAQ:BMEA - TradingView
Insiders Buying Biomea Fusion Might Wish They Invested More, Stock Gains 12% - simplywall.st
Enterprise value to EBITDA forward of Biomea Fusion, Inc. – NASDAQ:BMEA - TradingView
Enterprise value to EBIT forward of Biomea Fusion, Inc. – NASDAQ:BMEA - TradingView
Biomea Fusion Inc Actuals & Estimates (NASDAQ:BMEA) - TradingView
COVALENT-112 Phase II data boost momentum for ico, Biomea Fusion pushes first-in-class strategy - Traders Union
BMEA Forecast — Price Target — Prediction for 2027 - TradingView
Biomea Fusion forges new industry ties at BIO International Convention - Traders Union
Biomea Fusion Inc (BMEA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Biomea Fusion Inc (BMEA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Biomea Fusion Inc (BMEA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Biomea Fusion Inc (BMEA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Biomea Fusion Inc (BMEA) Institutional Confidence - TradingKey
Biomea Fusion Inc (BMEA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Biomea Fusion Inc (BMEA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Biomea Fusion Inc (BMEA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Team Fusion pinpoints this year leading trends at ADA2026 event - Traders Union
Biomea Fusion Inc (BMEA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Number of shareholders of Biomea Fusion, Inc. – NASDAQ:BMEA - TradingView
Biomea Fusion Q1 2026 Earnings: Narrower-Than-Expected Loss Signals Cost DisciplineOne-Time Gain Impact - newsline.com
Biomea Fusion Inc. Q1 2026 Earnings: EPS Beat on Cost Discipline as Biotech Advances PipelinePost-Announcement Reaction - newsline.com
[Form 4] Biomea Fusion, Inc. Insider Trading Activity - Stock Titan
Biomea Fusion (BMEA) director granted 196,299 stock options at $1.15 exercise price - Stock Titan
Biomea Fusion (BMEA) director Ray Sumita granted 196,299 stock options - Stock Titan
Biomea Fusion (BMEA) director receives 173,711-share stock option grant at $1.15 - Stock Titan
Citi Maintains Biomea Fusion(BMEA.US) With Buy Rating, Maintains Target Price $7 - Moomoo
Biomea Fusion (NASDAQ: BMEA) details 2026 director and auditor votes - Stock Titan
BMEA: Directors and auditors were approved by majority vote, with results to be filed with the SEC - TradingView
BMEA: All proposals, including director elections and auditor ratification, were approved - TradingView
Piper Sandler Maintains Biomea Fusion(BMEA.US) With Buy Rating, Maintains Target Price $7 - Moomoo
Biomea Fusion, Inc. (BMEA) Presents at American Diabetes Association (ADA) 86th Scientific SessionsSlideshow - Seeking Alpha
BMEA Q1 2026 Earnings: EPS Beat on Controlled Spending Overshadowed by Pipeline ConcernsAnalyst Drop Coverage - newsline.com
Biomea Fusion unveils new icovamenib data showing durable insulin secretion gains in T1D and T2D - Traders Union
Biomea Fusion shows promising diabetes and obesity drug data, expands Phase I study for weight loss therapy. - Pluang
Biomea Fusion Presents Promising Clinical Data for Icovamenib and Expands Phase I Study of BMF-650 at ADA 2026 - Quiver Quantitative
Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association ('ADA”) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study - The Manila Times
Biomea Fusion Says Icovamenib Data Show Muscle Preservation And Fat Reduction In Obesity And Diabetes - TradingView
Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“ADA”) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study - GlobeNewswire
BMEA: Phase II diabetes trials for a novel menin inhibitor target non-chronic, restorative therapy - TradingView
symbol__ Stock Quote Price and Forecast - CNN
Biomea Fusion to study icovamenib with semaglutide for weight loss - Investing.com UK
Icovamenib GLP-1 therapy combination evaluated in Biomea Fusion academic study - Traders Union
Biomea Fusion Announces Research Collaboration with University of Leicester to Evaluate Icovamenib in Combination with Semaglutide in Obesity - Investing News Network
Biomea Fusion to study icovamenib with semaglutide for weight loss By Investing.com - Investing.com South Africa
Biomea Fusion Announces Research Collaboration with - GlobeNewswire
Biomea Fusion icovamenib abstracts chosen for late-breaking poster presentations at diabetes conference - Traders Union
Biomea Fusion Q1 2026 Earnings: EPS Beats Estimates Despite No RevenueReturn On Assets - newsline.com
Biomea Fusion (BMEA) Holds Steady at $1.38, Testing Support as Traders Weigh Next MoveIsland Reversal - newsline.com
Biomea Fusion advances COVALENT-211 and COVALENT-212 research in type 2 diabetes - Traders Union
Biomea Fusion Inc Stock (BMEA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Biomea Fusion Inc Stock (BMEA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Hitchcock Michael J.M. | Interim CEO |
Dec 02 '25 |
Buy |
0.99 |
100,000 |
99,180 |
115,000 |
| Erdtmann Rainer M | See Remarks |
Nov 28 '25 |
Buy |
1.10 |
40,000 |
44,052 |
683,027 |
| Erdtmann Rainer M | See Remarks |
Dec 01 '25 |
Buy |
1.05 |
10,000 |
10,500 |
693,027 |
0.05%
0.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):